Diffuse gliomas continue to be an important problem in neuro-oncology. To solve it, studies have considered the issues of molecular pathogenesis from the intratumoral heterogeneity point. Here, we carried out a comparative dynamic analysis of the different cell populations’ content in diffuse gliomas of different molecular profiles and grades, considering the cell populations’ functional properties and the relationship with patient survival, using flow cytometry, immunofluorescence, multiparametric fluorescent in situ hybridization, polymerase chain reaction, and cultural methods. It was shown that an increase in the IDH-mutant astrocytomas and oligodendrogliomas malignancy is accompanied by an increase in stem cells’ proportion and mesenchymal cell populations’ appearance arising from oligodendrocyte-progenitor-like cells with cell plasticity and cells’ hypoxia response programs’ activation. In glioblastomas, malignancy increase is accompanied by an increase in both stem and definitive cells with mesenchymal differentiation, while proneuronal glioma stem cells are the most likely the source of mesenchymal glioma stem cells, which, in hypoxic conditions, further give rise to mesenchymal-like cells. Clinical confirmation was a mesenchymal-like cell and mesenchymal glioma stem cell number, and the hypoxic and plastic molecular programs’ activation degree had a significant effect on relapse-free and overall survival. In general, we built a multi-vector model of diffuse gliomas’ pathogenetic tracing up to the practical plane.

Systemic sclerosis (SSc), also known as scleroderma, is a chronic autoimmune condition primarily marked by skin and internal organ fibrosis.¹ Despite its rarity (400 cases per million or 150,000 cases in USA), SSc poses significant clinical challenges because over half of SSc patients succumb to the disease within a decade post-diagnosis.² Beyond its substantial mortality rate, SSc drastically deteriorates functionality and overall quality of life.^3,4 One of the key barriers to the lack of Food and Drug Administration (FDA)-approved treatments for SSc is the inability of current methods to provide reliable quantitative measurements of skin involvement in SSc.